Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Recruiting

Phase 1

ZEN003694 with Cetuximab, EncorafenibTesting the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT06102902

Conditions

Metastatic Colorectal Adenocarcinoma

Recurrent Colorectal Adenocarcinoma

Refractory Colorectal Adenocarcinoma

Stage IV Colorectal Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BET Bromodomain Inhibitor ZEN-3694

Biopsy Procedure

Biospecimen Collection

Cetuximab

Computed Tomography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-15.